IBDEI214 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,35464,2)
 ;;=^5061780
 ;;^UTILITY(U,$J,358.3,35465,0)
 ;;=Y36.7X0S^^187^2044^13
 ;;^UTILITY(U,$J,358.3,35465,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35465,1,3,0)
 ;;=3^War op w chem weapons and oth unconvtl warfare, milt, sqla
 ;;^UTILITY(U,$J,358.3,35465,1,4,0)
 ;;=4^Y36.7X0S
 ;;^UTILITY(U,$J,358.3,35465,2)
 ;;=^5061783
 ;;^UTILITY(U,$J,358.3,35466,0)
 ;;=E11.9^^188^2045^14
 ;;^UTILITY(U,$J,358.3,35466,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35466,1,3,0)
 ;;=3^Diabetes Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,35466,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,35466,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,35467,0)
 ;;=E10.9^^188^2045^13
 ;;^UTILITY(U,$J,358.3,35467,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35467,1,3,0)
 ;;=3^Diabetes Type 1 w/o Complications
 ;;^UTILITY(U,$J,358.3,35467,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,35467,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,35468,0)
 ;;=N18.9^^188^2045^10
 ;;^UTILITY(U,$J,358.3,35468,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35468,1,3,0)
 ;;=3^Chronic kidney disease, unspecified
 ;;^UTILITY(U,$J,358.3,35468,1,4,0)
 ;;=4^N18.9
 ;;^UTILITY(U,$J,358.3,35468,2)
 ;;=^332812
 ;;^UTILITY(U,$J,358.3,35469,0)
 ;;=D50.0^^188^2045^27
 ;;^UTILITY(U,$J,358.3,35469,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35469,1,3,0)
 ;;=3^Iron deficiency anemia secondary to blood loss (chronic)
 ;;^UTILITY(U,$J,358.3,35469,1,4,0)
 ;;=4^D50.0
 ;;^UTILITY(U,$J,358.3,35469,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,35470,0)
 ;;=D50.9^^188^2045^28
 ;;^UTILITY(U,$J,358.3,35470,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35470,1,3,0)
 ;;=3^Iron deficiency anemia, unspecified
 ;;^UTILITY(U,$J,358.3,35470,1,4,0)
 ;;=4^D50.9
 ;;^UTILITY(U,$J,358.3,35470,2)
 ;;=^5002283
 ;;^UTILITY(U,$J,358.3,35471,0)
 ;;=D62.^^188^2045^3
 ;;^UTILITY(U,$J,358.3,35471,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35471,1,3,0)
 ;;=3^Acute posthemorrhagic anemia
 ;;^UTILITY(U,$J,358.3,35471,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,35471,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,35472,0)
 ;;=D64.9^^188^2045^4
 ;;^UTILITY(U,$J,358.3,35472,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35472,1,3,0)
 ;;=3^Anemia, unspecified
 ;;^UTILITY(U,$J,358.3,35472,1,4,0)
 ;;=4^D64.9
 ;;^UTILITY(U,$J,358.3,35472,2)
 ;;=^5002351
 ;;^UTILITY(U,$J,358.3,35473,0)
 ;;=F03.90^^188^2045^12
 ;;^UTILITY(U,$J,358.3,35473,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35473,1,3,0)
 ;;=3^Dementia w/o behavioral disturbance,Unspec
 ;;^UTILITY(U,$J,358.3,35473,1,4,0)
 ;;=4^F03.90
 ;;^UTILITY(U,$J,358.3,35473,2)
 ;;=^5003050
 ;;^UTILITY(U,$J,358.3,35474,0)
 ;;=I10.^^188^2045^19
 ;;^UTILITY(U,$J,358.3,35474,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35474,1,3,0)
 ;;=3^Essential (primary) hypertension
 ;;^UTILITY(U,$J,358.3,35474,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,35474,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,35475,0)
 ;;=G45.9^^188^2045^43
 ;;^UTILITY(U,$J,358.3,35475,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35475,1,3,0)
 ;;=3^Transient cerebral ischemic attack, unspecified
 ;;^UTILITY(U,$J,358.3,35475,1,4,0)
 ;;=4^G45.9
 ;;^UTILITY(U,$J,358.3,35475,2)
 ;;=^5003959
 ;;^UTILITY(U,$J,358.3,35476,0)
 ;;=N18.4^^188^2045^9
 ;;^UTILITY(U,$J,358.3,35476,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35476,1,3,0)
 ;;=3^Chronic kidney disease, stage 4 (severe)
 ;;^UTILITY(U,$J,358.3,35476,1,4,0)
 ;;=4^N18.4
 ;;^UTILITY(U,$J,358.3,35476,2)
 ;;=^5015605
 ;;^UTILITY(U,$J,358.3,35477,0)
 ;;=R44.3^^188^2045^22
 ;;^UTILITY(U,$J,358.3,35477,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35477,1,3,0)
 ;;=3^Hallucinations, unspecified
 ;;
 ;;$END ROU IBDEI214
